PURPOSE: Imaging of the 18-kDa translocator protein (TSPO) is a potential tool for examining microglial activation and neuroinflammation in early Alzheimer's disease (AD). [(18)F]FEMPA is a novel high-affinity second-generation TSPO radioligand that has displayed suitable pharmacokinetic properties in preclinical studies. The aims of this study were to quantify the binding of [(18)F]FEMPA to TSPO in AD patients and controls and to investigate whether higher [(18)F]FEMPA binding in AD patients than in controls could be detected in vivo. METHODS: Ten AD patients (five men, five women; age 66.9 ± 7.3 years; MMSE score 25.5 ± 2.5) and seven controls (three men, four women; age 63.7 ± 7.2 years, MMSE score 29.3 ± 1.0) were studied using [(18)F]FEMPA at Turku (13 subjects) and at Karolinska Institutet (4 subjects). The in vitro binding affinity for TSPO was assessed using PBR28 in a competition assay with [(3)H]PK11195 in seven controls and eight AD patients. Cortical and subcortical regions of interest were examined. Quantification was performed using a two-tissue compartment model (2TCM) and Logan graphical analysis (GA). The outcome measure was the total distribution volume (V T). Repeated measures analysis of variance was used to assess the effect of group and TSPO binding status on V T. RESULTS: Five AD patients and four controls were high-affinity binders (HABs). Three AD patients and three controls were mixed-affinity binders. V T estimated with Logan GA was significantly correlated with V T estimated with the 2TCM in both controls (r = 0.97) and AD patients (r = 0.98) and was selected for the final analysis. Significantly higher V T was found in the medial temporal cortex in AD patients than in controls (p = 0.044) if the TSPO binding status was entered as a covariate. If only HABs were included, significantly higher V T was found in the medial and lateral temporal cortex, posterior cingulate, caudate, putamen, thalamus and cerebellum in AD patients than in controls (p < 0.05). CONCLUSION: [(18)F]FEMPA seems to be a suitable radioligand for detecting increased TSPO binding in AD patients if their binding status is taken into account.
PURPOSE: Imaging of the 18-kDa translocator protein (TSPO) is a potential tool for examining microglial activation and neuroinflammation in early Alzheimer's disease (AD). [(18)F]FEMPA is a novel high-affinity second-generation TSPO radioligand that has displayed suitable pharmacokinetic properties in preclinical studies. The aims of this study were to quantify the binding of [(18)F]FEMPA to TSPO in ADpatients and controls and to investigate whether higher [(18)F]FEMPA binding in ADpatients than in controls could be detected in vivo. METHODS: Ten ADpatients (five men, five women; age 66.9 ± 7.3 years; MMSE score 25.5 ± 2.5) and seven controls (three men, four women; age 63.7 ± 7.2 years, MMSE score 29.3 ± 1.0) were studied using [(18)F]FEMPA at Turku (13 subjects) and at Karolinska Institutet (4 subjects). The in vitro binding affinity for TSPO was assessed using PBR28 in a competition assay with [(3)H]PK11195 in seven controls and eight ADpatients. Cortical and subcortical regions of interest were examined. Quantification was performed using a two-tissue compartment model (2TCM) and Logan graphical analysis (GA). The outcome measure was the total distribution volume (V T). Repeated measures analysis of variance was used to assess the effect of group and TSPO binding status on V T. RESULTS: Five ADpatients and four controls were high-affinity binders (HABs). Three ADpatients and three controls were mixed-affinity binders. V T estimated with Logan GA was significantly correlated with V T estimated with the 2TCM in both controls (r = 0.97) and ADpatients (r = 0.98) and was selected for the final analysis. Significantly higher V T was found in the medial temporal cortex in ADpatients than in controls (p = 0.044) if the TSPO binding status was entered as a covariate. If only HABs were included, significantly higher V T was found in the medial and lateral temporal cortex, posterior cingulate, caudate, putamen, thalamus and cerebellum in ADpatients than in controls (p < 0.05). CONCLUSION: [(18)F]FEMPA seems to be a suitable radioligand for detecting increased TSPO binding in ADpatients if their binding status is taken into account.
Authors: Paul Edison; Hilary A Archer; Alexander Gerhard; Rainer Hinz; Nicola Pavese; Federico E Turkheimer; Alexander Hammers; Yen Fong Tai; Nick Fox; Angus Kennedy; Martin Rossor; David J Brooks Journal: Neurobiol Dis Date: 2008-08-15 Impact factor: 5.996
Authors: David R Owen; Owain W Howell; Sac-Pham Tang; Lisa A Wells; Idriss Bennacef; Mats Bergstrom; Roger N Gunn; Eugenii A Rabiner; Martin R Wilkins; Richard Reynolds; Paul M Matthews; Christine A Parker Journal: J Cereb Blood Flow Metab Date: 2010-04-28 Impact factor: 6.200
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: A Cagnin; D J Brooks; A M Kennedy; R N Gunn; R Myers; F E Turkheimer; T Jones; R B Banati Journal: Lancet Date: 2001-08-11 Impact factor: 79.321
Authors: L O Wahlund; F Barkhof; F Fazekas; L Bronge; M Augustin; M Sjögren; A Wallin; H Ader; D Leys; L Pantoni; F Pasquier; T Erkinjuntti; P Scheltens Journal: Stroke Date: 2001-06 Impact factor: 7.914
Authors: Alie Schuitemaker; Marc A Kropholler; Ronald Boellaard; Wiesje M van der Flier; Reina W Kloet; Thalia F van der Doef; Dirk L Knol; Albert D Windhorst; Gert Luurtsema; Frederik Barkhof; Cees Jonker; Adriaan A Lammertsma; Philip Scheltens; Bart N M van Berckel Journal: Neurobiol Aging Date: 2012-07-26 Impact factor: 4.673
Authors: Clayton A Wiley; Brian J Lopresti; Sriram Venneti; Julie Price; William E Klunk; Steven T DeKosky; Chester A Mathis Journal: Arch Neurol Date: 2009-01
Authors: J L E Bird; D Izquierdo-Garcia; J R Davies; J H F Rudd; K C Probst; N Figg; J C Clark; P L Weissberg; A P Davenport; E A Warburton Journal: Atherosclerosis Date: 2009-12-04 Impact factor: 5.162
Authors: Arthur L Brody; Robert Hubert; Ryutaro Enoki; Lizette Y Garcia; Michael S Mamoun; Kyoji Okita; Edythe D London; Erika L Nurmi; Lauren C Seaman; Mark A Mandelkern Journal: Neuropsychopharmacology Date: 2017-03-06 Impact factor: 7.853
Authors: Chad Brouwer; Kimberly J Jenko; Sami S Zoghbi; Cheryl L Morse; Robert B Innis; Victor W Pike Journal: Eur J Med Chem Date: 2016-08-25 Impact factor: 6.514
Authors: Arthur L Brody; Daniel Gehlbach; Lizette Y Garcia; Ryutaro Enoki; Carl Hoh; David Vera; Kishore K Kotta; Edythe D London; Kyoji Okita; Erika L Nurmi; Lauren C Seaman; Mark A Mandelkern Journal: Psychopharmacology (Berl) Date: 2018-10-20 Impact factor: 4.530
Authors: Sanna Hellberg; Johanna M U Silvola; Max Kiugel; Heidi Liljenbäck; Nina Savisto; Xiang-Guo Li; Andrea Thiele; Lutz Lehmann; Tobias Heinrich; Sonja Vollmer; Harri Hakovirta; V Jukka O Laine; Seppo Ylä-Herttuala; Juhani Knuuti; Anne Roivainen; Antti Saraste Journal: J Nucl Cardiol Date: 2016-05-25 Impact factor: 5.952